IgG4相关性疾病的管理和治疗:2015国际共识解读  

International consensus on the management and treatment of IgG4-Related diseases in 2015

作　　者：申嫒文 林鹭[1] 郁胜强[1] 

机构地区：[1]解放军肾脏病研究所上海长征医院肾内科,上海200443

出　　处：《中国实用内科杂志》2015年第12期1011-1014,共4页Chinese Journal of Practical Internal Medicine

摘　　要：IgG4相关性疾病是一个多器官受累的纤维炎症性疾病,近十年来医学界对它的认识逐渐增多。日本汇集了来自不同国家、不同专业的42名专家,对全球关于该疾病治疗方法总结后颁布此共识,为临床医生提供诊治指导。由于该疾病误诊率高,所以组织活检对该疾病的确诊具有重要的意义,能够排除恶性肿瘤和与IgG4相关性疾病有相似的临床和病理特征疾病。所有活动性的IgG4相关性疾病需进行积极有效的治疗,糖皮质激素是一线用药,但该疾病容易复发。IgG4-related disease is a fibroinflammatory disease that can affect multiple organs. Clinical experience with IgG4-RD has grown in the past few years .Japan gathered 42 experts from different countries and medical subspecialties to summarize treatment strategies used in different parts of the world. The goal is to provide guidance to clinicians. There are many diseases which mimic IgG4- RD clinically and histopathologically, so diagnosis through biopsy is very essential. All patients with symptomatic, active IgG4-RD require positive and effective treatment. Glucocorticoids are the first-line agent for remission induction, but this kind of disease is easy to

关 键 词：IGG4 IGG4相关性疾病 糖皮质激素 

分 类 号：R593.2[医药卫生—内科学]